

NILANDRON (nilutamide)

#### **Pre - PA Allowance**

None

# **Prior-Approval Requirements**

Age 18 years of age or older

Gender Male

#### Diagnosis

Patient must have the following:

- 1. Metastatic prostate cancer
  - AND all of the following:
    - a. Inadequate treatment response, intolerance, or contraindication to **ONE** of the following:
      - i. Generic nilutamide
      - ii. Bicalutamide
      - iii. Flutamide
    - b. Baseline liver enzymes test with NO severe hepatic impairment
    - c. Chest x-ray with NO severe respiratory insufficiency findings
    - d. Used in combination with surgical castration
    - e. **NO** dual therapy with another androgen receptor inhibitor (see Appendix 1)

### **Prior - Approval Limits**

Duration 12 months

## Prior – Approval Renewal Requirements

- Age 18 years of age or older
- Gender Male

#### Diagnosis

Patient must have the following:

1. Metastatic prostate cancer

**AND ALL** of the following:

a. NO severe respiratory insufficiency



- b. Prescriber agrees to monitor ALT and AST levels at regular intervals
- c. **NO** dual therapy with another androgen receptor inhibitor (see Appendix 1)

## Prior – Approval Renewal Limits

Same as above

### **Appendix 1 - List of Androgen Receptor Inhibitors**

Generic Name	Brand Name
abiraterone	Yonsa
abiraterone	Zytiga
abiraterone/niraparib	Akeega
apalutamide	Erleada
darolutamide	Nubeqa
enzalutamide	Xtandi
nilutamide	Nilandron